PDS Biotechnology Corp (PDSB) - Net Assets
Based on the latest financial reports, PDS Biotechnology Corp (PDSB) has net assets worth $9.25 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($30.49 Million) and total liabilities ($21.24 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of PDS Biotechnology Corp to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $9.25 Million |
| % of Total Assets | 30.34% |
| Annual Growth Rate | N/A |
| 5-Year Change | -85.36% |
| 10-Year Change | -89.64% |
| Growth Volatility | 69.86 |
PDS Biotechnology Corp - Net Assets Trend (2012–2025)
This chart illustrates how PDS Biotechnology Corp's net assets have evolved over time, based on quarterly financial data. Also explore PDSB current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for PDS Biotechnology Corp (2012–2025)
The table below shows the annual net assets of PDS Biotechnology Corp from 2012 to 2025. For live valuation and market cap data, see market value of PDS Biotechnology Corp.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $9.25 Million | -51.32% |
| 2024-12-31 | $19.00 Million | -27.27% |
| 2023-12-31 | $26.13 Million | -40.61% |
| 2022-12-31 | $44.00 Million | -30.39% |
| 2021-12-31 | $63.21 Million | +132.99% |
| 2020-12-31 | $27.13 Million | +131.92% |
| 2019-12-31 | $11.70 Million | -60.80% |
| 2018-12-31 | $29.84 Million | -52.16% |
| 2017-12-31 | $62.37 Million | -30.14% |
| 2016-12-31 | $89.28 Million | -27.11% |
| 2015-12-31 | $122.48 Million | +540.03% |
| 2014-12-31 | $-27.83 Million | -81.33% |
| 2013-12-31 | $-15.35 Million | -353.56% |
| 2012-12-31 | $-3.38 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to PDS Biotechnology Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20852900900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $18.11K | 0.20% |
| Other Components | $225.84 Million | 2441.03% |
| Total Equity | $9.25 Million | 100.00% |
PDS Biotechnology Corp Competitors by Market Cap
The table below lists competitors of PDS Biotechnology Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Falcon Machine Tools Co Ltd
TWO:4513
|
$54.77 Million |
|
biote Corp
NASDAQ:BTMD
|
$54.78 Million |
|
Wisekey International Holding AG
NASDAQ:WKEY
|
$54.81 Million |
|
Nahar Industrial Enterprises Limited
NSE:NAHARINDUS
|
$54.85 Million |
|
ImmuCell Corporation
NASDAQ:ICCC
|
$54.73 Million |
|
ZEN Graphene Solutions Ltd
NASDAQ:ZTEK
|
$54.73 Million |
|
Shinih Enterprise Co Ltd
TW:9944
|
$54.72 Million |
|
Tunas Alfin Tbk
JK:TALF
|
$54.72 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PDS Biotechnology Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 19,004,848 to 9,251,833, a change of -9,753,015 (-51.3%).
- Net loss of 36,835,144 reduced equity.
- New share issuances of 13,983,376 increased equity.
- Other factors increased equity by 13,098,753.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-36.84 Million | -398.14% |
| Share Issuances | $13.98 Million | +151.14% |
| Other Changes | $13.10 Million | +141.58% |
| Total Change | $- | -51.32% |
Book Value vs Market Value Analysis
This analysis compares PDS Biotechnology Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.92x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $-4.48 | $0.98 | x |
| 2013-12-31 | $-20.32 | $0.98 | x |
| 2014-12-31 | $-36.85 | $0.98 | x |
| 2015-12-31 | $87.33 | $0.98 | x |
| 2016-12-31 | $61.87 | $0.98 | x |
| 2017-12-31 | $41.04 | $0.98 | x |
| 2018-12-31 | $7.49 | $0.98 | x |
| 2019-12-31 | $2.40 | $0.98 | x |
| 2020-12-31 | $1.62 | $0.98 | x |
| 2021-12-31 | $2.47 | $0.98 | x |
| 2022-12-31 | $1.54 | $0.98 | x |
| 2023-12-31 | $0.84 | $0.98 | x |
| 2024-12-31 | $0.52 | $0.98 | x |
| 2025-12-31 | $0.20 | $0.98 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PDS Biotechnology Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -398.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 3.30x
- Recent ROE (-398.14%) is below the historical average (-91.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.36 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.35 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.42 Million |
| 2015 | -22.93% | 0.00% | 0.00x | 1.09x | $-40.33 Million |
| 2016 | -43.48% | 0.00% | 0.00x | 1.24x | $-47.75 Million |
| 2017 | -81.54% | 0.00% | 0.00x | 1.48x | $-57.10 Million |
| 2018 | -136.96% | 0.00% | 0.00x | 1.21x | $-43.85 Million |
| 2019 | -59.83% | 0.00% | 0.00x | 1.24x | $-8.17 Million |
| 2020 | -54.73% | 0.00% | 0.00x | 1.14x | $-17.56 Million |
| 2021 | -26.77% | 0.00% | 0.00x | 1.06x | $-23.24 Million |
| 2022 | -92.85% | 0.00% | 0.00x | 1.75x | $-45.26 Million |
| 2023 | -164.33% | 0.00% | 0.00x | 2.27x | $-45.56 Million |
| 2024 | -197.90% | 0.00% | 0.00x | 2.39x | $-39.51 Million |
| 2025 | -398.14% | 0.00% | 0.00x | 3.30x | $-37.76 Million |
Industry Comparison
This section compares PDS Biotechnology Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | $9.25 Million | 0.00% | 2.30x | $54.76 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, includin… Read more